FORMULATION AND IN VITRO EVALUATION OF GLICLAZIDE CONTAINING NIOSOMES

Abstract

In this study niosomal drug delivery system was developed using non-ionic surfactant incorporating Gliclazide by Thin film hydration technique. The prepared niosomal vesicles were quite stable. The formulation was subjected to Entrapment efficiency, Scanning electron microscopy, Invitro release, and Zeta potential analysis. From the results of experimental investigation, we concluded that, formulation F13 containing drug with 300:200 μmol (surfactant:cholesterol) ratio was showing higher percentage entrapment with desired sustained release of Gliclazide. Hence formulation F13 was considered as optimized formulation. Invitro release from optimized Gliclazide niosomal formulation (F13) showed extended release for 24 hours. SEM image revealed the vesicles are exist spherical shape and uniform in size. Scanning electron micrograph shows there is no aggregation between the particles. This confirmed the presence of negative charge inducing agent in formulation. The formulation was checked for sterility as per I.P specification. The optimized formulation passes the sterility test. Stability study was carried out for the period of three months at various storage conditions. The results showed that the formulation remains stable at 4°c. The optimized formulation was found to follow zero order release pattern which was revealed by the linearity shown from the plot of Time Vs cumulative percentage drug release. From the drug release kinetic studies, we concluded that the drug was released from niosome by a zero order diffusion controlled mechanism.